Search

Your search keyword '"Wu, Renrong"' showing total 453 results
Start Over Author "Wu, Renrong"
453 results on '"Wu, Renrong"'

10. Sulforaphane Effects on Cognition and Symptoms in First and Early Episode Schizophrenia: A Randomized Double-Blind Trial.

Author

Hei, Gangrui, Smith, Robert, Li, Ranran, Ou, Jianjun, Song, Xueqing, Zheng, Yingjun, He, Yiqun, Arriaza, Jen, Fahey, Jed, Cornblatt, Brian, Kang, Dongyu, Yang, Ye, Huang, Jing, Wang, Xiaoyi, Cadenhead, Kristin, Zhang, Mimei, Davis, John, Zhao, Jingping, Jin, Hua, and Wu, Renrong

Subjects
cognitive symptoms, psychiatric symptoms, schizophrenia, sulforaphane
Abstract

OBJECTIVE: Cognitive symptoms are associated with significant dysfunction in schizophrenia. Oxidative stress and inflammation involving histone deacetylase (HDAC) have been implicated in the pathophysiology of schizophrenia. Sulforaphane has antioxidant properties and is an HDAC inhibitor. The objective of this study was to determine the efficacy of sulforaphane on cognition dysfunction for patients with schizophrenia. METHODS: This double-blind randomized 22-week trial of patients with first-episode schizophrenia was conducted in four psychiatric institutions in China. Patients were randomized to three groups (two doses of sulforaphane vs. placebo) and symptomatic and cognitive assessments were completed at multiple times. The primary outcome measure was change in the MATRICS Composite score. The secondary outcomes were change in MATRICS Domain scores, PANSS Total Scores and change in side-effects. RESULTS: A total of 172 patients were randomized and 151 patients had at least one follow up evaluation. There were no significant effects of sulforaphane, on the primary outcome, MATRICS overall composite score. However, on secondary outcomes, sulforaphane did significantly improve performance scores on MATRICS battery Domains of spatial working memory (F = 5.68, P = 0.004), reasoning-problem solving (F = 2.82, P = 0.063), and verbal learning (F = 3.56, P = 0.031). There were no effects on PANSS symptom scores. Sulforaphane was well tolerated. CONCLUSION: Although the primary outcome was not significant, improvement in three domains of the MATRICS battery, suggests a positive cognitive effect on some cognitive functions, which warrants further clinical trials to further assess whether sulforaphane may be a useful adjunct for treating some types of cognitive deficits in schizophrenia.

Published
2022

13. Early non-response as a predictor of later non-response to antipsychotics in schizophrenia: a randomized trial

Author

Long, Yujun, Wu, Qiongqiong, Yang, Ye, Cai, Jingda, Xiao, Jingmei, Liu, Zhaoqian, Xu, Yifeng, Chen, Ying, Huang, Manli, Zhang, Ruiguo, Xu, Xijia, Hu, Jian, Liu, Zhifen, Liu, Fang, Zheng, Yingjun, Meng, Huaqing, Wang, Zhimin, Tang, Yanqing, Song, Xueqin, Chen, Yunchun, Wang, Xueyi, Liu, Tiebang, Wu, Xiaoli, Fang, Maosheng, Wan, Chunling, Zhao, Jingping, and Wu, Renrong

Published
2023
Full Text
View/download PDF

16. Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics

Author

Cai, Jingda, Li, Li, Shao, Tiannan, Sun, Mengxi, Wang, Weiyan, Xie, Peng, Wang, Xiaoyi, Yang, Ye, Long, Yujun, Kang, Dongyu, Xiao, Jingmei, Su, Yuhan, Peng, Xingjie, Huang, Yuyan, Gao, Menghui, Wu, Qiongqiong, Song, Chuhan, Liu, Furu, Shao, Ping, Ou, Jianjun, Shen, Yidong, Huang, Jing, and Wu, Renrong

Published
2023
Full Text
View/download PDF

38. The Effect of Accelerated Continuous Theta Burst Stimulation on Weight Loss in Overweight Individuals With Schizophrenia: A Double-Blind, Randomized, Sham-Controlled Clinical Trial.

Author

Kang, Dongyu, Zhang, Yi, Wu, Guowei, Song, Chuhan, Peng, Xinjie, Long, Yujun, Yu, Guo, Tang, Hui, Gui, Yawei, Wang, Quan, Yuan, Tifei, and Wu, Renrong

Subjects
BRAIN physiology, SCHIZOPHRENIA treatment, PREVENTION of obesity, WEIGHT loss, EMOTION regulation, BODY mass index, PSYCHIATRIC treatment, RESEARCH funding, STATISTICAL sampling, BODY weight, ELECTROENCEPHALOGRAPHY, SAMPLE size (Statistics), TREATMENT effectiveness, RANDOMIZED controlled trials, DESCRIPTIVE statistics, ATTENTION, FOOD habits, TRANSCRANIAL magnetic stimulation, ELECTROPHYSIOLOGY, EVALUATION
Abstract

Background and Hypothesis Obesity is a common comorbidity in individuals with schizophrenia and is associated with poor clinical outcomes. At present, there are limited effective approaches for addressing this issue. We conducted a double-blind, randomized, sham-controlled clinical trial to investigate the efficacy of noninvasive magnetic stimulation techniques in reducing obesity in individuals with schizophrenia. Study Design Forty overweight individuals with schizophrenia were recruited and randomly assigned to receive either the active or sham intervention. The active group received 50 accelerated continuous theta burst stimulation (cTBS) sessions over the left primary motor area (M1), while the sham group received sham stimulation. The primary outcomes were the change in body weight and body mass index (BMI), and the secondary outcomes were the psychiatric symptoms, eating behavior scales, metabolic measures, and electrophysiological to food picture stimuli. Study Results The study demonstrated a significant decrease in body weight and BMI after the intervention selectively in the active group (mean = −1.33 kg, P =.002), and this improvement remained at the 1-month follow-up (mean = −2.02 kg, P =.008). The score on the Barratt Impulsivity Scale (mean = −1.78, P = 0.036) decreased in the active group and mediated the effect of accelerated cTBS on body weight. In the food picture cue electroencephalograph task, the late positive potential component, which is related to motivated attention and emotional processing, decreased in frontal brain regions and increased in posterior regions after the active intervention. Conclusions The accelerated cTBS may offer a promising approach for treating obesity in individuals with schizophrenia. Further research with a larger sample size or individualized stimulation protocol should be promising. Trial Registration Clinical trial registered with clinicaltrials.gov (NCT05086133). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

46. The association of SOD and HsCRP with the efficacy of sulforaphane in schizophrenia patients with residual negative symptoms

Author

Zeng, Jianfei, primary, Zhang, Weizhi, additional, Lu, Xiaobing, additional, Zhou, Hui, additional, Huang, Jing, additional, Xu, Zhenyu, additional, Liao, Hairong, additional, Liang, Jiaquan, additional, Liang, Meihong, additional, Ye, Chan, additional, Sun, Ting, additional, Hu, Yutong, additional, She, Qi, additional, Chen, Haixia, additional, Guo, Qian, additional, Yan, LiuJiao, additional, Wu, Renrong, additional, and Li, Zezhi, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results